Objective To investigate the concentration of S-100 protein presenting in cerebrospinal fluid (CSF) and blood serum in patients with Guillain-Barr? syndrome (GBS), and discuss the value of assessment in measuring S-100 protein level to Schwann′s cell insult. Methods S-100 beta protein was measured dynamically by ELISA in CSF and blood serum from 50 patients with GBS and 22 referencesThe patients were divided into two categories by disease severity: the severe group and the mild groupMeanwhile, CSF cytology was also detected. Results (1) The level of CSF S-100 beta protein in both severe and mild groups were higher than that of the control group (P0.05)(2) The percentage of CSF monocyte in severe group was higher than that of the mild and the control groups(P0.05)(3) There was a dynamic change of CSF S-100 beta protein level in GBS patients correlated with the percentage of CSF monocyte and the severity of disease. Conclusions CSF and blood serum S-100 beta protein level in patients with GBS may be related to the severity of the disease.

In order to explore the value of assessment in measuring S-100 beta protein (S-100B protein) and neuron-specific enolase (NSE) present in cerebrospinal fluid (CSF) from patients with brain insult in central nervous system infections, S-100B protein and NSE in CSF were measured dynamically by ELISA in 42 patients with Herpes Simplex Encephalitis (USE), 19 patients with purulent meningitis, 17 patients with cryptococcus meningitis and 22 unrelated control patients. It was found that the levels of CSF S-100B protein in all the three groups were higher than that of the control group (P0. 05). There were dynamic changes of CSF S-100B protein and NSE concentrations in all three groups correlating with the severity of disease. It is suggested that elevated concentrations of S-100B protein and NSE in CSF related to the damage of glia and neurons could be used as CSF markers of brain insult in patients with central nervous system infections.

Objective To detect the expression of costimulatory molecules B7-H4 and programmed death ligand 1 (PD-L1) in bladder cancer,and to explore the correlation between them and clinicopathological features of bladder cancer.Methods Immunohistochemical staining was used to detect the expression of B7-H4 and PD-L1 in 98 cases of bladder urothelial carcinoma,which were confirmed by pathology from August 2014 to December 2015 in our hospital.There were 23 females,aged 45-82 years,with an average age of 67.8 years.Among them,42 cases of adjacent normal tissues were used as controls.The clinical stage,histological grade and recurrence of bladder cancer were collected,and the correlation between them was analyzed.Results The positive rates of B7-H4 and PD-L1 in bladder urothelial carcinoma were 54.1％ (53/98) and 59.2％ (58/98),respectively,and there was no expression in normal bladder tissues (P ＜ 0.05).The positive expression rate of B7-H4 in muscle invasive bladder cancer (MIBC) patients was higher than that in non-muscle invasive bladder cancer (NMIBC) [73.5％ (25/34) vs.43.8％ (28/64),P =0.005].The positive expression rate of B7-H4 in high-grade patients was higher than that of low-grade [70.0％ (21/30) vs.47.1％ (32/68),P =0.036].The expression rate of B7-H4 in high-risk group was higher than that of low-intermediate risk group [57.1％ (20/35) vs.27.6％ (8/29),P =0.018].The positive expression rate of PD-L1 in patients with MIBC was higher than that in NMIBC [79.4％ (27/34) vs.48.4％ (31/64),P =0.003].The PD-L1 expression rate of histological high-level group was higher than that of low-level group [73.3％ (22/30) vs.52.9％ (36/68)],but the difference was not statistically significant (P =0.058).The PD-L1 expression rate in high-risk group was 68.6％ (24/35),and also higher than low-middle group 24.1％ (7/29) (P ＜ 0.05).There was a positive correlation between the expression of B7-H4 and PD-L1 in bladder urothelial carcinoma (r =0.318,P=0.002).The combined recurrence rate of the two groups was significantly higher than that of the negative expression of the two groups [66.7％ (14/21) vs.30.8％ (8/26),P=0.014].Conclusions The expression of B7-H4 and PD-L1 is up-regulated in bladder urothelial carcinoma,which is closely related to the clinical stage,histological grade,risk classification and recurrence of NMIBC.

Objective To explore the status quo of medication belief in the patients with myasthenia gravis and analyze their influencing factors,so as to provide reference for health care professionals to develop targeted interventions.Methods A total of 145 patients with myasthenia gravis visiting the First Affiliated Hospital of Guangzhou University of Chinese Medicine from July 2021 to March 2022 were selected.The Be-liefs about Medicines Questionnaire(BMQ)was used to investigate.The multiple linear regression was used to analyze the relevant influencing factors.Results The scores of medication belief,necessity belief and con-cern belief in 145 patients were(4.17±1.23)points,(19.52±3.45)points and(18.29±4.26)points respec-tively.There was statistically significant difference between the scores of necessity belief and concern belief(P＜0.05).The education level,financial burden,duration of illness,length of medication,number of recur-rent hospitalizations,and inappropriate medication-induced exacerbations had influence on the medication be-lief scores of the patients with myasthenia gravis(P＜0.05).The duration of illness,length of medication and number of recurrent hospitalizations had the influence on the medication necessity scores of patients with my-asthenia gravis(P＜0.05).The financial burden had the influence on the medication concerns scores of the patients with myasthenia gravis(P＜0.05).Conclusion The medication belief in the patient swith myasthe-nia gravis is at a low level,and the number of recurrent hospitalizations and financial burden are the independ-ent risk factors affecting the medication belief scores in the patients with myasthenia gravis.The number of recurrent hospitalizations is an independent risk factor for the score of medication necessity dimension.